Ketaset

Manufactured by Henry Schein

Sourced in United Kingdom

Ketaset is a pharmaceutical product used as a general anesthetic in veterinary medicine. It contains the active ingredient ketamine hydrochloride. The primary function of Ketaset is to induce anesthesia and provide pain relief for animals undergoing medical procedures.

Automatically generated - may contain errors

Lab products found in correlation

Addavax adjuvant, by InvivoGen (2 mentions)

5 protocols using ketaset

Pigtail Macaque RBD-12GS-I53-50 Nanoparticle Vaccine

Check if the same lab product or an alternative is used in the 5 most similar protocols

A Pigtail macaque was immunized with 250 μg of RBD-12GS-I53-50 nanoparticle (88 μg RBD antigen) at day 0 and day 28. Blood was collected at days 0, 10, 14, 28, 42, and 56 days post-prime. Blood was collected in serum collection tubes and allowed to clot at room temperature. Serum was isolated after a 15 min spin at 1455 x g for 15 min and stored at −80C until use. Prior to vaccination or blood collection, animals were sedated with an intramuscular injection (10 mg/kg) of ketamine (Ketaset®; Henry Schein). Prior to inoculation, immunogen suspensions were gently mixed 1:1 vol/vol with AddaVax adjuvant (Invivogen, San Diego, CA) to reach a final concentration of 0.250 mg/mL antigen. The vaccine was delivered intramuscularly into both quadriceps muscles with 1 mL per injection site on days 0 and 28. All injection sites were shaved prior to injection. Animals were observed daily for general health (activity and appetite, urine/feces output) and for evidence of reactogenicity at the vaccine inoculation site (swelling, erythema, and pruritus) for up to 1 week following vaccination. They also received physical exams including temperature and weight measurements at each study time point. None of the animals became severely ill during the course of the study nor required euthanasia.

Walls A.C., Fiala B., Schäfer A., Wrenn S., Pham M.N., Murphy M., Tse L.V., Shehata L., O’Connor M.A., Chen C., Navarro M.J., Miranda M.C., Pettie D., Ravichandran R., Kraft J.C., Ogohara C., Palser A., Chalk S., Lee E.C., Guerriero K., Kepl E., Chow C.M., Sydeman C., Hodge E.A., Brown B., Fuller J.T., Dinnon KH I.I.I., Gralinski L.E., Leist S.R., Gully K.L., Lewis T.B., Guttman M., Chu H.Y., Lee K.K., Fuller D.H., Baric R.S., Kellam P., Carter L., Pepper M., Sheahan T.P., Veesler D, & King N.P. (2020). Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell, 183(5), 1367-1382.e17.

+ Open protocol

+ Expand

Ketamine Dosage and Administration for Behavioural Studies

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Ketamine hydrochloride (Ketaset, Henry Schein Animal Health, UK) was diluted in a normal saline vehicle to 25 mg/mL or 8 mg/mL and administered intraperitoneally (IP) at 1 mL/kg 30 min prior or immediately following conditioning training or recall trials. The resulting subanaesthetic doses of 25 mg/kg or 8 mg/kg are consistent with previous studies (Bolton et al., 2012 (link); Razoux et al., 2007 (link)).

Clifton N.E., Thomas K.L, & Hall J. (2018). The effect of ketamine on the consolidation and extinction of contextual fear memory. Journal of Psychopharmacology (Oxford, England), 32(2), 156-162.

+ Open protocol

+ Expand

Stereotaxic Implantation of pDLS Cannulae in Rats

Check if the same lab product or an alternative is used in the 5 most similar protocols

Rats were anesthetized with intramuscular injections of a mixture of ketamine (Ketaset; Henry Schein, Dumfries, Scotland, 0.1 ml/100 g body weight) and xylazine (Rompun; Henry Schein, 0.05 ml/100 g body weight). Each rat was placed into a stereotaxic frame (David Kopf, USA) and implanted with guide cannulae (24-gauge, 11-mm; Cooper’s Needleworks) targeting the pDLS, using the following co-ordinates (mm): AP −0.4 mm, ML ±4.0 mm (from bregma), DV −3.8 mm (from the skull surface). Wire stylets (Cooper’s Needleworks) were inserted into the guide cannulae to maintain patency. Rats were allowed at least 7 days of recovery from surgery before behavioral procedures began.

Cahill E.N., Vousden G.H., Exton-McGuinness M.T., Beh I.R., Swerner C.B., Macak M., Abas S., Cole C.C., Kelleher B.F., Everitt B.J, & Milton A.L. (2018). Knockdown of zif268 in the Posterior Dorsolateral Striatum Does Not Enduringly Disrupt a Response Memory of a Rewarded T-Maze Task. Neuroscience, 370, 112-120.

+ Open protocol

+ Expand

Rhesus Macaque RBD Nanoparticle Vaccine

Check if the same lab product or an alternative is used in the 5 most similar protocols

Two Pigtail macaques were immunized with 250 μg of RBD-12GS-I53-50 nanoparticle (88 μg RBD antigen) with AddaVax at day 0, day 28, and O/W at day 168. Blood was collected every 14 days post-prime. Blood was collected in serum collection tubes and allowed to clot at room temperature. Serum was isolated after a 15 min spin at 1455 x g for 15 min and stored at −80C until use. Prior to vaccination or blood collection, animals were sedated with an intramuscular injection (10 mg/kg) of ketamine (Ketaset®; Henry Schein). Prior to inoculation, immunogen suspensions were gently mixed 1:1 vol/vol with AddaVax adjuvant for immunizations 1 and 2 and O/W for immunization 3 (VFI) to reach a final concentration of 0.250 mg/mL antigen. The vaccine was delivered intramuscularly into both quadriceps muscles with 1 mL per injection site on days 0, 28, and 168. All injection sites were shaved prior to injection. Animals were observed daily for general health (activity and appetite, urine/feces output) and for evidence of reactogenicity at the vaccine inoculation site (swelling, erythema, and pruritus) for up to 1 week following vaccination. They also received physical exams including temperature and weight measurements at each study time point. None of the animals became severely ill during the course of the study nor required euthanasia.

Walls A.C., Miranda M.C., Schäfer A., Pham M.N., Greaney A., Arunachalam P.S., Navarro M.J., Tortorici M.A., Rogers K., O’Connor M.A., Shirreff L., Ferrell D.E., Bowen J., Brunette N., Kepl E., Zepeda S.K., Starr T., Hsieh C.L., Fiala B., Wrenn S., Pettie D., Sydeman C., Sprouse K.R., Johnson M., Blackstone A., Ravichandran R., Ogohara C., Carter L., Tilles S.W., Rappuoli R., Leist S.R., Martinez D.R., Clark M., Tisch R., O’Hagan D.T., Van Der Most R., Van Voorhis W.C., Corti D., McLellan J.S., Kleanthous H., Sheahan T.P., Smith K.D., Fuller D.H., Villinger F., Bloom J., Pulendran B., Baric R.S., King N.P, & Veesler D. (2021). Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell, 184(21), 5432-5447.e16.

+ Open protocol

+ Expand

Pigtail Macaque Immunized with RBD Nanoparticle

Check if the same lab product or an alternative is used in the 5 most similar protocols

A Pigtail macaque was immunized with 250 μg of RBD-12GS-I53–50 nanoparticle (88 μg RBD antigen) at day 0 and day 28. Blood was collected at days 0, 10, 14, 28, 42, and 56 days post-prime. Serum and plasma were collected as previously described (Erasmus et al., 2020 ). Prior to vaccination or blood collection, animals were sedated with an intramuscular injection (10 mg/kg) of ketamine (Ketaset®; Henry Schein). Prior to inoculation, immunogen suspensions were gently mixed 1:1 vol/vol with AddaVax adjuvant (Invivogen, San Diego, CA) to reach a final concentration of 0.250 mg/mL antigen. The vaccine was delivered intramuscularly into both quadriceps muscles with 1 mL per injection site on days 0 and 28. All injection sites were shaved prior to injection and monitored post-injection for any signs of local reactogenicity. At each study timepoint, full physical exams and evaluation of general health were performed on the animals, as previously described (Erasmus et al., 2020 ), and no adverse events were observed.

Walls A.C., Fiala B., Schäfer A., Wrenn S., Pham M.N., Murphy M., Tse L.V., Shehata L., O’Connor M.A., Chen C., Navarro M.J., Miranda M.C., Pettie D., Ravichandran R., Kraft J.C., Ogohara C., Palser A., Chalk S., Lee E.C., Kepl E., Chow C.M., Sydeman C., Hodge E.A., Brown B., Fuller J.T., Dinnon KH I.I.I., Gralinski L.E., Leist S.R., Gully K.L., Lewis T.B., Guttman M., Chu H.Y., Lee K.K., Fuller D.H., Baric R.S., Kellam P., Carter L., Pepper M., Sheahan T.P., Veesler D, & King N.P. (2020). Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. bioRxiv.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!